Title
Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST
Author
Dusinska, M.
Boland, S.
Saunders, M.
Juillerat-Jeanneret, L.
Tran, L.
Pojana, G.
Marcomini, A.
Volkovova, K.
Tulinska, J.
Knudsen, L.E.
Gombau, L.
Whelan, M.
Collins, A.R.
Marano, F.
Housiadas, C.
Bilanicova, D.
Halamoda Kenzaoui, B.
Correia Carreira, S.
Magdolenova, Z.
Fjellsbo, L.M.
Huk, A.
Handy, R.
Walker, L.
Barancokova, M.
Bartonova, A.
Burello, E.
Castell, J.
Cowie, H.
Drlickova, M.
Guadagnini, R.
Harris, G.
Harju, M.
Heimstad, E.S.
Hurbankova, M.
Kazimirova, A.
Kovacikova, Z.
Kuricova, M.
Liskova, A.
Milcamps, A.
Neubauerova, E.
Palosaari, T.
Papazafiri, P.
Pilou, M.
Poulsen, M.S.
Ross, B.
Runden-Pran, E.
Sebekova, K.
Staruchova, M.
Vallotto, D.
Worth, A.
Publication year
2015
Abstract
In spite of recent advances in describing the health outcomes of exposure to nanoparticles (NPs), it still remains unclear how exactly NPs interact with their cellular targets. Size, surface, mass, geometry, and composition may all play a beneficial role as well as causing toxicity. Concerns of scientists, politicians and the public about potential health hazards associated with NPs need to be answered. With the variety of exposure routes available, there is potential for NPs to reach every organ in the body but we know little about the impact this might have. The main objective of the FP7 NanoTEST project (www.nanotest-fp7.eu) was a better understanding of mechanisms of interactions of NPs employed in nanomedicine with cells, tissues and organs and to address critical issues relating to toxicity testing especially with respect to alternatives to tests on animals. Here we describe an approach towards alternative testing strategies for hazard and risk assessment of nanomaterials, highlighting the adaptation of standard methods demanded by the special physicochemical features of nanomaterials and bioavailability studies. The work has assessed a broad range of toxicity tests, cell models and NP types and concentrations taking into account the inherent impact of NP properties and the effects of changes in experimental conditions using well-characterized NPs. The results of the studies have been used to generate recommendations for a suitable and robust testing strategy which can be applied to new medical NPs as they are developed. © 2015 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted.
Subject
Life
RAPID - Risk Analysis for Products in Development
ELSS - Earth, Life and Social Sciences
Biomedical Innovation
Biology
Healthy Living
Hazard assessment
in vitro
Nanoparticles
NanoTEST
Testing strategy
Nanomaterial
Adsorption
Bioavailability
Cell activation
Cellular distribution
Chemical composition
Concentration (parameters)
Crystal structure
Dispersion
Hazard assessment
High throughput screening
Hydrophobicity
Material coating
Micronucleus test
Molecular interaction
Nanomedicine
Neutron scattering
Oxidative stress
Particle size
PH
Physical chemistry
Quantitative structure activity relation
Risk assessment
Salinity
Solubility
Standard
Surface charge
Surface property
Temperature
Toxicity assay
Toxicity testing
Transport assay
Transport kinetics
Water hardness
Animalia
To reference this document use:
http://resolver.tudelft.nl/uuid:e2046201-1dbe-44df-a1f0-b838e19733a6
DOI
https://doi.org/10.3109/17435390.2014.991431
TNO identifier
526108
ISSN
1743-5390
Source
Nanotoxicology, 9 (S1), 118-132
Document type
article